Key Statistics for THR
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (EUR) (ttm)
|Est. EPS (EUR) (12/2013)
|Est. PEG Ratio
|Market Cap (M EUR)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for THR
- Net Income (M/EUR)
ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.
More Company Profile & Key Executives for THR
|Desire CollenChairman/Founder||Patrik De HaesCEO/Executive Director|
|Chris BuyseCFO/Executive Director/Secy||Koen KasChief Scientific Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries